Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

Inclusion Criteria: * Histologic proof of cancer which is now not amenable to alternative curative or clearly superior standard treatment options * Measurable disease * Hemoglobin (Hgb) \>= 8.0 g/dL * Absolute neutrophil count (ANC) \>= 1,500/uL * Platelet (PLT) = 100,000/uL * Activated partial thromboplastin time (APTT) \< 1.2 times upper limit of normal (ULN); (Note: use of warfarin is prohibited; low molecular weight heparin is allowed, so long as these criteria are met) * International normalized ratio (INR) \< 1.2 times ULN; (Note: use of warfarin is prohibited; low molecular weight heparin is allowed, so long as these criteria are met) * Direct bilirubin =\< 1.5 X upper limit of normal (ULN) (subjects with Gilbert's syndrome and elevations of indirect bilirubin only are eligible) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 2.5 X ULN * Creatinine =\< 1.5 times ULN OR measured creatinine clearance of \>= 60 mL/min 1.73 m\^2 * Urine protein/creatinine ratio \< 1 or 24-hour urine \< 1 gram * \< Grade 2 hypo/hyperkalemia * \< Grade 3 hypo/hypercalcemia * \< Grade 3 hypo/hyperphosphatemia * \< Grade 3 hypo/hypermagnesemia * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Ability to provide informed consent * Willing to return to Mayo Clinic for follow up * Life expectancy \>= 84 days (3 months) * Willingness to provide mandatory blood samples for pazopanib drug level assessments required for dosage adju…